The accelerated approval of Fabhalta for the treatment of primary IgA nephropathy is based on positive results from the Phase 3 APPLAUSE-IgAN trial.
FDA grants accelerated approval to Novartis’ Favarta for primary IgA nephropathy
You Might Also Like
Leave a Comment
Latest News
Recent Posts
- How e-wallets in Asia-Pacific are leading the way towards cashlessness
- Kiwi chefs prepare for ‘culinary Olympics’ at France’s Bocuse d’Or final
- Superbank announces $300 million IPO size in Jakarta by year-end
- Thunes enables real-time payments for hyperwallet merchants in Asia Pacific
- CFPB claims Capital One kept customers in the dark